Fierce Biotech Names Abdera Therapeutics a “Fierce 15” Biotech Company of 2024
SOUTH SAN FRANCISCO, CA, August 5, 2024 – Abdera Therapeutics Inc., a biopharmaceutical company leveraging its advanced antibody engineering ROVEr™ platform to design and develop tunable, precision radiopharmaceuticals for cancer, today announced that Fierce Biotech has named it as one of 2024’s “Fierce 15” biotechnology companies. The annual special report features the most innovative and promising biotechnology companies in the industry.
“We are honored to be recognized among this year’s distinguished group of Fierce 15 winners,” said Lori Lyons-Williams, president and chief executive officer of Abdera. “We have made strong progress and are preparing to begin our first clinical study for our lead program ABD-147, the first precision radiopharmaceutical therapy targeting DLL3 being advanced for the treatment of small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC). The U.S. Food and Drug Administration recently granted Fast Track designation to ABD-147 for the treatment of patients with extensive stage small cell lung cancer, which we see as an opportunity to remain relentless in our mission to transform the way people living with cancer are treated. I am proud of our team’s hard work and dedication as we leverage our proprietary ROVEr™ platform to develop next-generation precision radiopharmaceutical biologic therapies to address a variety of cancers where new treatment options are needed.”
Abdera’s Radio Optimized Vector Engineering (ROVEr™) platform enables the company to custom-engineer targeted radiopharmaceuticals with tunable pharmacokinetic (PK) properties to achieve high tumor uptake while minimizing renal exposure and mitigating other systemic radiotoxicities such as myelosuppression. Through this platform, Abdera can optimize the delivery and therapeutic index of potent radioisotopes capable of emitting powerful alpha or beta particles to selectively destroy tumor cells while sparing healthy cells. Importantly, Abdera’s approach offers the ability to design radiopharmaceuticals against virtually any cancer target expressed on the cell surface, including both high- and low-expressing targets.
“For the past 22 years, we have evaluated hundreds of companies for inclusion in the ‘Fierce 15’ special report. Our selection process considers various factors, including technological robustness, strategic partnerships, venture support and market positioning,” said Ayla Ellison, Editor-in-Chief, Fierce Life Sciences and Healthcare. “This report highlights innovation and creativity amid intense competition.”
About Fierce Biotech
Fierce Biotech is the biotech industry’s daily monitor, providing the latest news, articles, and resources related to clinical trials, drug discovery, FDA approval, FDA regulation, patent news, pharma news, biotech company news and more. More than 300,000 top biotech professionals rely on Fierce Biotech for an insider briefing on the day’s top stories.
About Abdera
Abdera Therapeutics is a biopharmaceutical company leveraging antibody engineering to design and develop new precision radiopharmaceuticals for cancer. Abdera’s Radio Optimized Vector Engineering (ROVEr™) platform enables the company to engineer potential best-in-class therapies for both clinically validated and novel targets that deliver potent radioisotopes capable of emitting alpha or beta particles to selectively destroy cancer cells. Abdera’s lead program, ABD-147, is a next-generation precision radiopharmaceutical biologic therapy designed to deliver Actinium-225 (225Ac) to solid tumors expressing delta-like ligand 3 (DLL3) for the treatment of small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC). Headquartered in South San Francisco, CA, Abdera also has offices in Vancouver, British Columbia, Canada. To learn more, please visit www.abderatx.com and follow us on LinkedIn and X.
Contacts:
Media:
1AB
Katie Engleman
katie@1abmedia.com
Investors:
1AB
Steve Klass
Steve@1abmedia.com